Walt O.
Bilateral knee replacement recommended. Prediabetes at the T2D threshold. Sleeping in a recliner. His PCP said weight gain was just part of aging. It wasn't.
48 lbs lost in 7 months. Knee surgery deferred indefinitely. Walked every shore excursion on the European river cruise he thought he'd miss. And got on the floor with his grandkids for the first time in three years.
The Decade He Planned — and the Body That Wasn't Ready
Walt is a 67-year-old retired mechanical engineer with 35 years at a defense contractor — precise, analytical, and deeply frustrated. He walks with a noticeable limp. He sleeps in a recliner four nights a week because lying flat hurts too much. He cannot get on the floor with his four grandkids. His orthopedic surgeon recommended bilateral knee replacement six months ago. He refused — not because he denied the severity, but because he knew, as an engineer, that surgical outcomes are measurably worse in heavier patients, and he wasn't going under the knife at suboptimal weight if he had any say in the matter.
He had tried. He did Atkins twice — lost 30+ lbs each time, regained both times. In 2019, he built his own calorie-tracking spreadsheet, ran it rigorously for 14 months, lost 22 lbs, and regained. He tried Silver Sneakers. His knees hurt too much after three weeks. Two rounds of physical therapy helped the pain temporarily but produced no meaningful weight change. His PCP's perspective: weight gain is just part of aging.
Walt and his wife have a European river cruise booked. He had been quietly terrified he would be the one sitting on the boat while she explored the cities. He came to FLOA with a clear engineering-style objective: lose enough weight to optimize surgical outcomes if surgery is ultimately necessary, avoid a T2D diagnosis, and be functional enough to live the active retirement he and his wife had planned. He also came with four previous weight-cycling episodes behind him and zero interest in a fifth.
What Arrived at 67 After a Decade of Weight Cycling
- Bilateral knee osteoarthritis — orthopedic surgeon recommended replacement; sleeping in recliner 4 nights/week
- HbA1c 6.3% — at the cusp of Type 2 diabetes; fasting glucose 116, postprandial glucose 168
- Significant insulin resistance: HOMA-IR 6.3, fasting insulin 22 mIU/L
- Triglycerides 198, HDL 38 — dyslipidemia consistent with metabolic syndrome
- hs-CRP 6.2 mg/L — significantly elevated, driven by osteoarthritis load plus metabolic inflammation
- Testosterone 312 ng/dL (symptomatic low end), estradiol 38 — elevated from adipose aromatization
- TSH 3.4, free T3 2.6 — suboptimal thyroid function flagged "normal" by PCP
- Sleep efficiency 67% — chronic disruption from knee pain; recliner sleeping fragmenting architecture nightly
- Sarcopenia risk: 67-year-old male with four prior weight-cycling episodes — lean mass protection non-negotiable
- On five medications: lisinopril 20mg, atorvastatin, meloxicam 15mg, tramadol, baby aspirin — polypharmacy management required throughout
- Cannot walk meaningful distances, play with grandkids on floor, or trust his knees for international travel
Engineering the Outcome — Slow, Safe, and Muscle-Protective
Full metabolic, hormone, inflammation, and lipid subfraction panel. Vitamin D, B12, ferritin. DEXA at baseline — non-negotiable for a 67-year-old with four prior weight cycles, to establish the lean mass protection benchmark before a single pound was lost. Medication interaction review covering tirzepatide compatibility with his cardiovascular medications and the specific meloxicam/GLP-1 GI risk profile. Sarcopenia risk documented and built into every downstream decision.
Tirzepatide selected over semaglutide for its stronger metabolic effect given Walt's near-T2D HbA1c and elevated triglycerides — both respond well to the dual GIP/GLP-1 mechanism. Started at 2.5mg with deliberately slow titration for an older patient; older GI systems are less tolerant of rapid escalation. Held at 5mg throughout the entire 7-month program. No escalation beyond minimum effective dose. Reduced the all-day retirement grazing pattern that had replaced the structured eating his work schedule once provided.
BPC-157 oral protocol added at month 2 specifically for joint and connective tissue support given bilateral knee osteoarthritis. BPC-157 promotes angiogenesis in damaged tissue, supports tendon and ligament repair, and has demonstrated anti-inflammatory activity in musculoskeletal applications. Added only after month 1 tirzepatide tolerance was confirmed. The combination of mechanical load reduction from weight loss and BPC-157 tissue-level support contributed to knee pain dropping from 8/10 to 5/10 by month 2.
Pool walking 3x/week. Seated resistance training 3x/week focused on lower body strength without joint loading. Recumbent bike for Zone 2 cardio. No running. No standard squats. No treadmill. The program was designed entirely around Walt's actual knee capacity — not a generic older adult program adapted after the fact. The seated resistance training preserved and built the lower body musculature that would be essential for post-surgical recovery if surgery was ultimately required, while avoiding the loading that had been causing his pain.
140g protein daily — aggressively prioritized given age and sarcopenia risk. The engineering-retiree breakfast and lunch pattern (bagels, sandwiches, carb-heavy) was identified as a major contributor to both insulin resistance and inadequate protein. Rebuilt around eggs, lean meats, Greek yogurt, and protein supplementation. Strategic carbohydrate reduction targeting the prediabetes trajectory: consistent under 100g/day during the weight loss phase — not keto, but structured and glucose-managed.
Testosterone optimization not initiated in Phase 1. The medical team's hypothesis: at 312 ng/dL with elevated estradiol from adipose aromatization, fat loss would reduce aromatization and allow testosterone to recover naturally. Month 3 recheck confirmed it — testosterone rose to 412 ng/dL without any exogenous intervention. TRT avoided at 67. The same secondary-to-adiposity pattern that resolved for Justin H. at 36 resolved for Walt at 67.
Phase by Phase
Out of the Recliner — Sleep Improving
Down 11 lbs. Sleep improved as the recliner became unnecessary four nights a week — the first meaningful functional recovery signal. Energy stable despite his age and medication load. No GI side effects despite the age and meloxicam combination — a real clinical concern going in that the slow titration strategy successfully managed. Retirement grazing pattern quieted within two weeks of initiation.
→ Down 11 lbs; recliner no longer needed 4 nights; sleep improving
BPC-157 Added — Knee Pain 5/10 — 1.2 Miles Without Stopping
Down 21 lbs. BPC-157 oral protocol initiated. Knee pain reported as 5/10 rather than 8/10 at baseline — the combination of 21 lbs of load removed and BPC-157's tissue-level activity working simultaneously. Walt walked 1.2 miles without stopping for the first time in four years. That milestone mattered more to him than any lab number.
→ Down 21 lbs; knee pain 5/10; 1.2-mile walk completed for first time in 4 years
Labs Confirm Reversal — Muscle Preserved on DEXA — Testosterone Recovering
Down 31 lbs. HbA1c 5.8% — out of the near-T2D range. Fasting insulin 13, HOMA-IR 2.8, triglycerides 132, hs-CRP 2.4. Testosterone retested: 412 ng/dL — up 100 points without TRT. DEXA confirmed muscle mass preserved within 0.5 lbs of baseline at month 3. Every marker moving. Nothing lost.
→ Down 31 lbs; HbA1c 5.8%; T 412 without TRT; muscle preserved on DEXA
PCP Halves His Blood Pressure Medication — Floor Time With Grandkids
Down 42 lbs. PCP reduced lisinopril from 20mg to 10mg — one of the five medications Walt had been on for 11 years beginning to be deprescribed as blood pressure normalized with weight loss. He got on the floor with his grandkids for the first time in three years. That was the outcome he had named on intake as the one that mattered most. It happened at month 5.
→ Down 42 lbs; lisinopril halved; on the floor with grandkids month 5
Surgery Deferred — Cruise Walked — 48 lbs Gone
Down 48 lbs at 204 lbs. Orthopedic surgeon reassessed both knees and recommended deferring surgery indefinitely — the outcome Walt had structured his entire protocol around. Tirzepatide held at 5mg the entire program — never escalated. He took the European river cruise and walked every shore excursion. His wife did not explore the cities without him.
→ 48 lbs lost; surgery deferred; every shore excursion walked; cruise complete
"Walt's PCP told him weight gain was just part of aging. His HOMA-IR was 6.3 and his HbA1c was 6.3 — he was approaching a Type 2 diabetes diagnosis and his surgeon was recommending bilateral knee replacement. None of that is inevitable. At 67, the intervention window is narrower, the muscle preservation imperative is higher, and the medication management is more complex — but the biology still responds. Sarcopenia and metabolic disease are not aging. They are modifiable outcomes with the right protocol."
What Changed at 7 Months
Surgery Deferred
Bilateral knee replacement recommended at intake — deferred indefinitely at month 7 orthopedic reassessment. Knee pain from 8/10 to manageable without tramadol. Meloxicam deprescribed entirely.
Body Composition at 67
48 lbs lost (252 → 204). DEXA confirmed 50 lbs fat lost and 2 lbs lean muscle gained — an extraordinary result for a 67-year-old male with four prior weight cycles and bilateral joint disease.
T2D Threshold Reversed
HbA1c from 6.3 → 5.6%. Fasting insulin from 22 → 11 mIU/L. HOMA-IR from 6.3 → 2.5. Triglycerides from 198 → 118. HDL from 38 → 48. The diabetes trajectory his PCP hadn't flagged as urgent — reversed.
Medications Reduced
Lisinopril halved from 20mg to 10mg. Meloxicam deprescribed entirely. Tramadol no longer needed. From five medications to three — the deprescribing outcome his PCP had not anticipated.
Testosterone — No TRT
Total testosterone from 312 → 428 ng/dL without exogenous intervention. Adipose-driven aromatization reduced as fat mass dropped — estradiol normalized, testosterone recovered naturally at 67.
The Life He Planned
Walked every shore excursion on the European river cruise. Gets on the floor with four grandkids. Walks 2+ miles daily without pain. Reports feeling 15 years younger — the active retirement he designed, now accessible.
| Category | What Changed |
|---|---|
| Knee Surgery | Recommended bilaterally → deferred indefinitely at month 7 orthopedic reassessment |
| Knee Pain | 8/10 chronic → manageable without tramadol; walking 2+ miles daily without a limp |
| Sleep | Recliner 4 nights/week → sleeping in bed every night by month 1 |
| Grandkids | Floor play impossible for 3 years → on the floor with all four grandkids at month 5 |
| The Cruise | Feared missing shore excursions → walked every single one |
| Lisinopril | 20mg for 11 years → reduced to 10mg at month 5 by PCP |
| Meloxicam | Daily 15mg for knee pain → deprescribed entirely |
| Tramadol | Occasional use for pain management → no longer needed |
| Testosterone | 312 → 428 ng/dL without TRT; estradiol normalized; adipose aromatization reversed |
| Lean Mass | +2 lbs on DEXA at 67 — muscle gained during weight loss; sarcopenia actively prevented |
"I'm an engineer. I tried to solve this myself — I built a calorie spreadsheet and ran it for 14 months. Lost 22 pounds, put it all back. My doctor said weight gain is just part of aging. My orthopedic surgeon said both knees needed replacing. FLOA said let's address the underlying biology and see what changes. Seven months later I've lost 48 pounds, the surgeon told me to hold off on surgery indefinitely, I walked every port on our river cruise, and I got on the floor with my grandkids for the first time in three years. I feel fifteen years younger. That's not aging. That's what was available when someone actually tried."
Clinical Takeaways
Walt's case makes an argument that older patients deserve to hear more often: metabolic disease and physical decline in your 60s are not the same as aging. His HOMA-IR of 6.3, his near-T2D HbA1c, his elevated inflammatory markers, and his knee pain were all modifiable. His PCP framed them as expected. That framing — "weight gain is just part of aging" — is clinically inaccurate and practically harmful, because it removes the patient's agency over outcomes that are still fully addressable with the right intervention.
The sarcopenia imperative at 67 shaped every protocol decision. A 67-year-old male losing 48 lbs without a plan for muscle preservation will arrive lighter and weaker — a metabolically worse outcome than staying heavier. The DEXA at baseline, month 3, and month 6 was not optional. The 140g protein target, the seated resistance training program, and the slow tirzepatide titration were all specifically designed to lose fat while protecting the lean mass that will determine Walt's functional capacity for the next two decades. The DEXA confirmed it worked: 50 lbs of fat lost, 2 lbs of lean muscle gained at 67.
The BPC-157 addition at month 2 deserves specific attention. The knee pain reduction from 8/10 to 5/10 — enabling the walking capacity that hadn't been available for four years — was driven by two simultaneous mechanisms: 21 lbs of mechanical load removed from damaged cartilage, and BPC-157's tissue-level anti-inflammatory and repair activity addressing the connective tissue environment directly. The orthopedic surgeon who recommended bilateral knee replacement at baseline recommended deferring surgery indefinitely at month 7. That outcome was not incidental. It was engineered.
Weight Gain Is Not Just Part of Aging — and Neither Is What Comes With It
If you've been told that your weight, your joints, or your labs are just what 60 looks like — get a second opinion. The biology responds at 67. The muscle preservation imperative is real, the medication management is more complex, and the protocol has to match the patient. But the window is still open.
Individual results vary. This case study is for educational purposes only. © Dr. Jones DC — FLOA Protocol.